Physician profile

Stephen W Tobia

Obstetrics & Gynecology · Melbourne, FL

NPI 1932303336

$247.44

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$25.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $64.07 2019-2023 Liletta
Hologic Sales and Service, LLC $41.07 2019
Amag Pharmaceuticals, INC. $27.76 2019
Mylan Pharmaceuticals INC. $24.21 2021
Therapeuticsmd, INC. $20.76 2019
Merck Sharp & Dohme LLC $17.32 2020
Duchesnay USA Incorporated $17.24 2019
Pfizer INC. $15.60 2019
Coopersurgical, INC. $11.30 2020
Meditrina $8.11 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen W Tobia

$247.44

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/87950/stephen-w-tobia

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.